IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

ACADIA PHARMACEUTICALS INC.,)
Plaintiff,)
v.) C.A. No
MSN LABORATORIES PRIVATE LTD. and MSN PHARMACEUTICALS, INC.,)))
Defendants.)

SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)

Plaintiff hereby provides the information below with respect to the deadlines set forth in 21 U.S.C. 355(j):

Date Patentee Received Notice: June 18, 2020

Date of Expiration of Patent: Patent No. 7,732,615 – June 3, 2028

Patent No. 10,646,480 – August 27, 2038

Thirty Month Stay Deadline: December 18, 2022 (statutory)

October 29, 2023 (extended)¹

Dated: July 30, 2020

_

¹ As Plaintiff is entitled to NCE market exclusivity and is filing this action in the 1-year period beginning 4 years after first NDA approval (Apr 29, 2016), the 30-month stay is extended by 7.5 years from the date of first NDA approval, which is October 29, 2023.

OF COUNSEL:

Chad J. Peterman
Bruce M. Wexler
Scott F. Peachman
PAUL HASTINGS LLP
200 Park Avenue
New York, New York 10166
(212) 318-6000
chadpeterman@paulhastings.com
brucewexler@paulhastings.com
scottpeachman@paulhastings.com

Attorneys for Plaintiff ACADIA Pharmaceuticals Inc.

SAUL EWING ARNSTEIN & LEHR LLP

/s/James D. Taylor, Jr.
James D. Taylor, Jr. (#4009)
Jessica M. Jones (#6246)
Charles E. Davis (#6402)
1201 N. Market Street, Suite 2300
P.O. Box 1266
Wilmington, Delaware 19899
(302) 421-6800
James.Taylor@saul.com
Jessica.Jones@saul.com
Chad.Davis@saul.com